

Dr. Mrinal Gounder, MD, is an internationally recognized, medical oncologist and investigator who holds dual appointments in sarcoma and early drug development (phase 1) programs at MSKCC. After finishing his internal medicine residency at Northwestern in Chicago, he pursued fellowship in medical oncology where he remains as a faculty. He specializes in developing new drugs across solid tumors with a specific focus on sarcoma and rare cancers. He is the principal investigator of several global clinical trials (phase I – III) that have been practice changing including the phase 2 study that led to the US FDA approval of tazemetostat in epithelioid sarcoma. His original research has been published in the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Nature Medicine, Nature Communications and others. His research contributions to drug development in rare cancers were recognized as the top 10 Advances of the Year in 2018 by ASCO. He is the MSKCC Physician Ambassador to India and Asia, and under his leadership MSK is building cancer care networks in Asia to improve access to patient care, education, graduate medical training, and advancing cancer research and clinical trials.